Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC-19PD1 CAR-T in R/R B-cell Lymphoma
NCT03932955Phase 1Unknown
- Sponsor
- Peking University
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MC-19PD1 CAR-T cells in B cell lymphoma, sponsored by Peking University. Primary endpoint: Percentage of adverse events at 2 years. Status: unknown.
02
Drugs
MC-19PD1 CAR-T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03932955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932955.